Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

2026-03-16 - 12:23

PALO ALTO, Calif. & HONG KONG -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the ShieldTM multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. Read More